Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

5.97
Delayed Data
As of Feb 16
 +0.18 / +3.11%
Today’s Change
4.60
Today|||52-Week Range
11.72
+0.34%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$419.5M

Company Description

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipelines are therapeutic agents, imaging agents for prostate cancer, and imaging analysis tools. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Contact Information

Progenics Pharmaceuticals, Inc.
One World Trade Center
New York New York 1000
P:(646) 975-2500
Investor Relations:
(646) 975-2533

Employees

Shareholders

Mutual fund holders55.03%
Other institutional33.15%
Individual stakeholders12.33%

Top Executives

Mark Robert BakerChief Executive Officer & Director
Patrick FabbioCFO, Principal Accounting Officer & Senior VP
Jessica JensenVice President-Clinical Development
Vivien WongVice President-Product Development
Jeffrey D. SummerSenior Vice President-Strategy & Performance